HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist BET protein bromodomain antagonists (BAs) have been shown to inhibit growth, induce apoptosis and exert promising anti-acute myeloid leukemia (AML) activity, especially against those AML cells that display genetic mutation in NPM1, MLL, FLT3, IDH2 and EVI1. [1] [2] [3] [4] [5] [6] BAs, such as the prototype JQ1, disrupt the binding of the BET proteins, for example, BRD4 to acetylated histones. 7, 8 This inhibits the BRD4-mediated recruitment of the positive transcription elongation factor b (pTEFb), a heterodimer of CDK9 and cyclin T1, for inducing RNA polymerase-II (RNAP2) phosphorylation. 7, 8 pTEFb phosphorylates serine-2 in the C-terminal domain heptad repeats Y 1 S 2 P 3 T 4 S 5 P 6 S 7 of RNAP2, which induces the pause release of RNAP2, allowing productive mRNA transcript elongation. 8, 9 The pTEFb-induced phosphorylation events are considered to be rate limiting for the RNAP2-mediated elongation of mRNA transcripts, including those of several oncogenes such as Myc, BCL2 and CDK4/6 in AML cells. 1, 2, [8] [9] [10] Consistent with this, treatment with JQ1 has been shown to reduce the levels of c-Myc, CDK6 and BCL2, associated with growth inhibition and apoptosis of human AML blast progenitor cells (BPCs). 1, 2, 6 BA treatment also induces the mRNA and protein expression of hexamethylene bisacetamideinducible protein 1 (HEXIM1) in AML cells. 6, 8, 11 HEXIM1 inhibits pTEFb by binding to cyclin T1 and sequestering pTEFb into an inhibitory complex that also contains the small noncoding RNA 7SK. 8, 11 HEXIM1 can form homodimers or heterodimers with the closely related but distinct gene product HEXIM2. 11, 12 Multiple
Accepted article preview online 15 June 2015; advance online publication, 7 July 2015 pTEFb units bind to a HEXIM1 multimer. 12, 13 By sequestering and inhibiting pTEFb, and in turn RNAP2, HEXIM1 may be mechanistically involved in mediating BA-induced growth inhibition, differentiation and apoptosis of AML cells. [8] [9] [10] [11] [12] Interrogation of The Cancer Genome Atlas (TCGA) database using the cBioPortal for Cancer Genomics demonstrated that HEXIM1 mRNA overexpression is almost mutually exclusive with c-Myc overexpression in AML (Figure 1a) . 14 Of the 200 AML samples, 22 samples showed c-Myc and 12 samples HEXIM1 overexpression (Figure 1a ). Only one sample showed overexpression of both genes ( Figure 1a ). Collectively, these observations created the rationale for further determining the mechanistic role of BA-induced HEXIM1 in mediating the growth inhibition, differentiation and apoptosis of AML BPCs owing to treatment with BA.
In the present studies, we first knocked down the mRNA and protein expression of HEXIM1 in the cultured AML MOLM13 and Figure 1f ). We also transduced the HEXIM1 shRNA into freshly procured pAML BPCs expressing FLT3-ITD (pAML-HKD cells). As shown in Figure 1g , compared with the pAML cells transduced with non-targeted shRNA (pAML-NT cells), pAML-HKD cells expressed markedly lower protein levels of HEXIM1 but higher levels of c-Myc, whereas HEXIM2 levels were similar in the two cell types. Notably, treatment with JQ1 induced HEXIM1 in pAML-NT but not in pAML-HKD cells, whereas HEXIM2 levels remained unperturbed (Figure 1g ). JQ1 treatment also attenuated c-Myc levels (Figure 1g ). Concomitantly, JQ1 treatment induced differentiation in a greater percentage of pAML-NT BPCs, as compared with pAML-HKD cells (Figure 1h ). Moreover, treatment with JQ1 dose-dependently induced significantly more apoptosis of pAML-NT, as compared with pAML-HKD BPCs (Figure 1i ).
In the nucleus, the regulatory subunit of pTEFb, cyclin T1, binds to CDK9 or to the C-terminal domain of HEXIM1, 11 based on which we determined the effect of HEXIM1 knockdown on the binding of cyclin T1 to HEXIM1 and CDK9 in unperturbed and JQ1-treated MOLM13-NT cells. In the unperturbed MOLM13-NT cells, immunoprecipitated cyclin T1 bound to HEXIM1 and CDK9 (Supplementary Figure 1a) . Treatment with JQ1 increased the levels and binding of immunoprecipitated cCyclin T1 to HEXIM1, which was not observed in MOLM13-HKD cells (Supplementary Figure 1a) . JQ1 treatment also caused increased binding of cyclin T1 to CDK9 in both MOLM13-NT and MOLM13-HKD cells (Supplementary Figure 1a) , without causing increase in the levels of cyclin T1 and CDK9 (Supplementary Figure 1b) . These results were confirmed by confocal immunofluorescence microscopy, which also demonstrated that the nuclear colocalization of cyclin T1 and HEXIM1 in MOLM13-NT cells was not observed in MOLM13-HKD cells (Supplementary Figure 1c) . Moreover, increased nuclear colocalization of cyclin T1 and HEXIM1 in MOLM13-NT cells because of JQ1 treatment was abrogated in MOLM13-HKD cells (Supplementary Figure 1c) .
We next determined the in vivo anti-AML activity of JQ1 against the xenografts of MOLM13-HKD cells compared with the xenografts of MOLM13-NT cells. Two weeks after a tail vein infusion of the MOLM13-NT or MOLM13-HKD cells into the NOD/ SCID (nonobese diabetic/severe-combined immunodeficiency) mice, mice engrafted with the AML cells were treated with either vehicle alone or JQ1 for 3 weeks. In an additional cohort of mice treated identically with either vehicle alone or JQ1 for 5 days, the bone marrow and spleen were harvested to determine the protein expression of HEXIM1, cyclin T1 and CDK9. As shown in Figure 2a , compared with treatment with vehicle alone, JQ1 treatment significantly improved the median survival of the mice engrafted with MOLM13-NT (P o 0.005). In contrast, following JQ1 treatment, the improvement in the median survival was significantly compromised in the mice engrafted with MOLM13-HKD cells (P o 0.01). Notably, in vivo treatment with JQ1 markedly induced the protein expression of HEXIM1 in the AML cells harvested from the bone marrow of mice engrafted with MOLM13-NT but not of the MOLM13-HKD cells (Figure 2b) . Following JQ1 treatment, the protein levels of CDK9 were comparable in the engrafted MOLM13-NT and MOLM13-HKD AML cells (Figure 2b) .
We next determined the effects of lentivirus-transduced tetracycline-inducible, ectopic expression of FLAG-tagged HEXIM1 on JQ1-mediated growth inhibition, differentiation and apoptosis of MOLM13 AML cells (MOLM-HIN cells). Figure 2c cells to 0.5 μg/ml of tetracycline markedly induced the expression of HEXIM1, without affecting the levels of CDK9 or cyclin T1. This was associated with a marked attenuation of the suspension culture growth of MOLM-HIN cells (Supplementary Figure 2) . Following treatment with JQ1 (100 nM) for 96 h, as compared with the uninduced cells, tetracycline-induced MOLM-HIN cells demonstrated more profound morphologic features of differentiation (Figure 2d ). Treatment with JQ1 further and significantly increased the percentage of differentiated MOLM-HIN cells that had been exposed to tetracycline (P o 0.01) (Figure 2e) . Notably, treatment with JQ1 for 48 h also induced significantly more apoptosis of tetracycline-exposed MOLM-HIN cells, as compared with those untreated with tetracycline ( Figure 2f) .
The amount and availability of the free and active pTEFb, for mediating RNAP2 pause release, is negatively controlled by its binding to the ribonucleoprotein complex containing HEXIM1 and snRNA 7SK, a complex in which up to half of the nuclear pTEFb may be sequestered. 8, 9 This suggests that the nuclear levels of HEXIM1 would influence the growth of the transformed cells by controlling gene expression that regulates cell growth. 8, 11 Consistent with The Cancer Genome Atlas data, our findings also demonstrate that knockdown of nuclear HEXIM1 is associated with an increase in c-Myc levels. These perturbations in HEXIM1 and c-Myc expressions increased the in vitro growth of the AML cells. However, HEXIM1 knockdown appeared to exert little effect on the in vivo growth of MOLM13-HKD cells, as the survival of the NOD/SCID mice engrafted with MOLM13-HKD cells was similar to those engrafted with MOLM13-NT cells. As noted above, BRD4 may directly recruit pTEFb to activate transcription, or the ET domain of BRD4 may activate transcription independent of pTEFb by recruiting the arginine demethylase JMJD6 or NSD3. 8 This would explain why knockdown of HEXIM1 would not influence all transcription regulated by BRD4.
Collectively, these findings demonstrate that BA-mediated HEXIM1 induction mechanistically regulates BA-induced differentiation and apoptosis of cultured and primary AML BPCs. Further development and in vivo testing of BAs against AML, with careful attention given to HEXIM1 induction as a predictive biomarker of anti-AML activity of BA, is warranted. It would also be important to develop and test other novel agents that induce HEXIM1 for their ability to mediate growth inhibition, differentiation and apoptosis of AML BPCs, especially of the genetic subtypes noted above. 15 
